Logo do repositório
 
Publicação

The prevalence and determinants of neuropsychiatric symptoms in late‐stage Parkinsonism

dc.contributor.authorHommel, Adrianus L. A. J.
dc.contributor.authorMeinders, Marjan J.
dc.contributor.authorLorenzl, Stefan
dc.contributor.authorDodel, Richard
dc.contributor.authorCoelho, Miguel
dc.contributor.authorFerreira, Joaquim J
dc.contributor.authorLaurens, Brice
dc.contributor.authorSpampinato, Umberto
dc.contributor.authorMeissner, Wassilios
dc.contributor.authorRosqvist, Kristina
dc.contributor.authorTimpka, Jonathan
dc.contributor.authorOdin, Per
dc.contributor.authorWittenberg, Michael
dc.contributor.authorBloem PhD, Bas R.
dc.contributor.authorKoopmans, Raymond T.
dc.contributor.authorSchrag, Anette
dc.date.accessioned2021-02-24T13:37:47Z
dc.date.available2021-02-24T13:37:47Z
dc.date.issued2020
dc.description© 2020 International Parkinson and Movement Disorder Societypt_PT
dc.description.abstractBackground: Late-stage parkinsonism and Parkinson's disease (PD) are insufficiently studied population. Although neuropsychiatric symptoms (eg, psychosis, depression, anxiety, behavioral problems) are frequently present, their prevalence and clinical predictors remain unknown. Objective: To determine the prevalence and predictors of neuropsychiatric symptoms in late-stage PD. Methods: We conducted a multinational study of patients with PD with ≥7 years disease duration and either a Hoehn and Yahr stage ≥4 or a Schwab and England score ≤ 50% in the on stage. Neuropsychiatric symptoms were assessed through interviews with carers using the Neuropsychiatric Inventory, with a frequency × severity score ≥ 4, indicating clinically relevant symptoms. The determinants analyzed were demographic characteristics, medication, and motor and nonmotor symptoms. Univariate and multivariate logistic analyses were performed on predictors of clinically relevant neuropsychiatric symptoms. Results: A total of 625 patients were recruited in whom the Neuropsychiatric Inventory could be completed. In 92.2% (576/625) of the patients, at least 1 neuropsychiatric symptom was present, and 75.5% (472/625) had ≥1 clinically relevant symptom. The most common clinically relevant symptoms were apathy (n = 242; 38.9%), depression (n = 213; 34.5%), and anxiety (n = 148; 23.8%). The multivariate analysis revealed unique sets of predictors for each symptom, particularly the presence of other neuropsychiatric features, cognitive impairment, daytime sleepiness. Conclusion: Neuropsychiatric symptoms are common in late-stage PD. The strongest predictors are the presence of other neuropsychiatric symptoms. Clinicians involved in the care for patients with late-stage PD should be aware of these symptoms in this specific disease group and proactively explore other psychiatric comorbidities once a neuropsychiatric symptom is recognized.pt_PT
dc.description.sponsorshipThe Care of late-stage Parkinsonism-study (CLaSP) is being funded by the European Commission (Joint Programme–Neurodegenerative DiseaseResearch “European Research Projects for the Evaluation of Health Care Policies, Strategies and Interventions for Neurodegenerative Diseases”) through national funding bodies in all 6 countries(Economic and Social Research Council ES/L009250/1; BMBF, Marburg, Germany 01ED1403A, Munich, Germany 01ED1403B; Bordeaux, France, ANR-13-JPHC-0001-07; Lisbon, Portugal, HC/0002/2012; Lund, Sweden, HC-559-002; Nijmegen, Hol-land, 733051003). A.L.A.J.H. was supported by the Groenhuysen organization and Stichting Beroepsopleiding Huisartsen. A.S. was supported by the National Institute for Health Research University College London/University College London Hospital Biomedical Research Centre.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMov Disord Clin Pract. 2020 May 21;7(5):531-542pt_PT
dc.identifier.doi10.1002/mdc3.12968pt_PT
dc.identifier.eissn2330-1619
dc.identifier.urihttp://hdl.handle.net/10451/46504
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherJohn Wiley & Sons, Inc.pt_PT
dc.relationCare for Late Stage Parkinsonism
dc.relation.publisherversionhttps://movementdisorders.onlinelibrary.wiley.com/journal/23301619pt_PT
dc.subjectLate‐stage parkinsonismpt_PT
dc.subjectNeuropsychiatric symptomspt_PT
dc.subjectPrevalencept_PT
dc.subjectPsychosispt_PT
dc.subjectDepressionpt_PT
dc.titleThe prevalence and determinants of neuropsychiatric symptoms in late‐stage Parkinsonismpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardNumberJPND-HC/0002/2012
oaire.awardTitleCare for Late Stage Parkinsonism
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/JPND-HC%2F0002%2F2012/PT
oaire.citation.endPage542pt_PT
oaire.citation.issue5pt_PT
oaire.citation.startPage531pt_PT
oaire.citation.titleMovement Disorders Clinical Practicept_PT
oaire.citation.volume7pt_PT
oaire.fundingStream3599-PPCDT
person.familyNameCoelho
person.familyNameFerreira
person.givenNameMiguel
person.givenNameJoaquim J
person.identifier1624753
person.identifier.ciencia-id3312-A6EB-631D
person.identifier.ciencia-id7D15-5CD6-6159
person.identifier.orcid0000-0002-4008-8110
person.identifier.orcid0000-0003-3950-5113
person.identifier.scopus-author-id7101666975
person.identifier.scopus-author-id7403252466
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationb1ae9a1f-31c1-42f5-80e0-9383914a671f
relation.isAuthorOfPublication54d84fe7-2cbd-4ddc-bce2-0ff2bd7c4cc9
relation.isAuthorOfPublication.latestForDiscovery54d84fe7-2cbd-4ddc-bce2-0ff2bd7c4cc9
relation.isProjectOfPublication8e1e953f-7d9c-4d6a-9dcb-2e63ba544f15
relation.isProjectOfPublication.latestForDiscovery8e1e953f-7d9c-4d6a-9dcb-2e63ba544f15

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Stage_Parkinson.pdf
Tamanho:
275.73 KB
Formato:
Adobe Portable Document Format